PT1373259E - Inibidores piridazinona de aldose reductase - Google Patents
Inibidores piridazinona de aldose reductaseInfo
- Publication number
- PT1373259E PT1373259E PT02716247T PT02716247T PT1373259E PT 1373259 E PT1373259 E PT 1373259E PT 02716247 T PT02716247 T PT 02716247T PT 02716247 T PT02716247 T PT 02716247T PT 1373259 E PT1373259 E PT 1373259E
- Authority
- PT
- Portugal
- Prior art keywords
- pyridazinone
- inhibitors
- aldose reductase
- aldose
- reductase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28005101P | 2001-03-30 | 2001-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1373259E true PT1373259E (pt) | 2005-03-31 |
Family
ID=23071435
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02716247T PT1373259E (pt) | 2001-03-30 | 2002-01-31 | Inibidores piridazinona de aldose reductase |
| PT04023149T PT1491540E (pt) | 2001-03-30 | 2002-01-31 | Intermediários úteis na síntese de inibidores piridazinona de aldose reductase |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT04023149T PT1491540E (pt) | 2001-03-30 | 2002-01-31 | Intermediários úteis na síntese de inibidores piridazinona de aldose reductase |
Country Status (44)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE41920E1 (en) | 1996-07-24 | 2010-11-09 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
| ES2240657T3 (es) * | 2001-02-28 | 2005-10-16 | Pfizer Products Inc. | Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa. |
| AU2002226634B2 (en) * | 2001-03-30 | 2007-01-25 | Pfizer Products Inc. | Pyridazinone aldose reductase inhibitors |
| AU761191B2 (en) * | 2001-05-24 | 2003-05-29 | Pfizer Products Inc. | Therapies for tissue damage resulting from ischemia |
| PL371258A1 (en) | 2002-01-09 | 2005-06-13 | Pfizer Products Inc. | Process and intermediates for pyridazinone antidiabetic agents |
| US20040092522A1 (en) * | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
| US7419981B2 (en) * | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US6872833B2 (en) * | 2003-04-14 | 2005-03-29 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| EP1750862B1 (en) | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| WO2006028565A2 (en) * | 2004-06-30 | 2006-03-16 | Whitehead Institute For Biomedical Research | Novel methods for high-throughput genome-wide location analysis |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| MX2008009022A (es) * | 2006-01-13 | 2008-09-24 | Wyeth Corp | 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina. |
| ME00535B (me) | 2006-06-27 | 2011-10-10 | Takeda Pharmaceuticals Co | Fuzionisana ciklična jedinjenja |
| CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
| US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
| WO2011071995A2 (en) | 2009-12-08 | 2011-06-16 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| TWI464147B (zh) * | 2011-09-15 | 2014-12-11 | Univ Taipei Medical | 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途 |
| US9339542B2 (en) * | 2013-04-16 | 2016-05-17 | John L Couvaras | Hypertension reducing composition |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| CN103739547B (zh) * | 2014-01-03 | 2015-09-02 | 沈阳药科大学 | 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法 |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| EP3283074A4 (en) * | 2015-04-14 | 2018-12-05 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| CN115160339B (zh) | 2016-06-21 | 2024-05-14 | 纽约市哥伦比亚大学理事会 | 醛糖还原酶抑制剂及其使用方法 |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| US10344002B2 (en) | 2016-09-26 | 2019-07-09 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15 PGDH INHIBITORS WITH CORTICOSTEROIDS AND / OR TNF INHIBITORS AND USES THEREOF |
| WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| MX2020001057A (es) | 2017-07-28 | 2020-11-24 | Applied Therapeutics Inc | Composiciones y metodos para tratar la galactosemia. |
| CN113574055A (zh) | 2019-01-18 | 2021-10-29 | 阿斯利康(瑞典)有限公司 | Pcsk9抑制剂及其使用方法 |
| JP2022534426A (ja) | 2019-05-31 | 2022-07-29 | イケナ オンコロジー， インコーポレイテッド | Ｔｅａｄ阻害剤およびその使用 |
| CN114502540A (zh) | 2019-05-31 | 2022-05-13 | 医肯纳肿瘤学公司 | Tead抑制剂和其用途 |
| WO2022120353A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47592B1 (en) | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| US4996204A (en) | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
| FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
| WO1992009594A1 (en) * | 1990-11-30 | 1992-06-11 | Tsumura & Co. | Chromone derivative and aldose reductase inhibitor containing the same as active ingredient |
| BR9205810A (pt) | 1991-03-28 | 1994-06-28 | Pfizer | Acidos piridazinona acéticos |
| US5834466A (en) | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
| TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| AU735729B2 (en) * | 1997-09-24 | 2001-07-12 | Orion Corporation | Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors |
| FR2822827B1 (fr) * | 2001-03-28 | 2003-05-16 | Sanofi Synthelabo | Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant |
| AU2002226634B2 (en) * | 2001-03-30 | 2007-01-25 | Pfizer Products Inc. | Pyridazinone aldose reductase inhibitors |
| AU2002236131B2 (en) * | 2001-04-30 | 2005-04-14 | Pfizer Products Inc. | Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors |
| PL371258A1 (en) * | 2002-01-09 | 2005-06-13 | Pfizer Products Inc. | Process and intermediates for pyridazinone antidiabetic agents |
-
2002
- 2002-01-31 AU AU2002226634A patent/AU2002226634B2/en not_active Ceased
- 2002-01-31 PT PT02716247T patent/PT1373259E/pt unknown
- 2002-01-31 UA UA2003098846A patent/UA73236C2/uk unknown
- 2002-01-31 CA CA002442476A patent/CA2442476A1/en not_active Abandoned
- 2002-01-31 IL IL15646202A patent/IL156462A0/xx unknown
- 2002-01-31 PT PT04023149T patent/PT1491540E/pt unknown
- 2002-01-31 EP EP02716247A patent/EP1373259B1/en not_active Expired - Lifetime
- 2002-01-31 DK DK02716247T patent/DK1373259T3/da active
- 2002-01-31 JP JP2002577823A patent/JP2004528319A/ja active Pending
- 2002-01-31 BR BR0208571-2A patent/BR0208571A/pt not_active IP Right Cessation
- 2002-01-31 AT AT02716247T patent/ATE286049T1/de active
- 2002-01-31 EE EEP200300470A patent/EE200300470A/xx unknown
- 2002-01-31 CN CNB028076001A patent/CN1215067C/zh not_active Expired - Fee Related
- 2002-01-31 DK DK04023149T patent/DK1491540T3/da active
- 2002-01-31 EP EP04023149A patent/EP1491540B1/en not_active Expired - Lifetime
- 2002-01-31 EA EA200300673A patent/EA006023B1/ru not_active IP Right Cessation
- 2002-01-31 SK SK1185-2003A patent/SK11852003A3/sk unknown
- 2002-01-31 WO PCT/IB2002/000320 patent/WO2002079198A1/en active IP Right Grant
- 2002-01-31 ES ES04023149T patent/ES2274369T3/es not_active Expired - Lifetime
- 2002-01-31 OA OA1200300222A patent/OA12453A/en unknown
- 2002-01-31 AT AT04023149T patent/ATE348100T1/de not_active IP Right Cessation
- 2002-01-31 SI SI200230071T patent/SI1373259T1/xx unknown
- 2002-01-31 AT AT04023150T patent/ATE352551T1/de not_active IP Right Cessation
- 2002-01-31 NZ NZ528406A patent/NZ528406A/en unknown
- 2002-01-31 DE DE60217930T patent/DE60217930T2/de not_active Expired - Fee Related
- 2002-01-31 KR KR1020037012753A patent/KR100586138B1/ko not_active IP Right Cessation
- 2002-01-31 DE DE60216823T patent/DE60216823T2/de not_active Expired - Fee Related
- 2002-01-31 YU YU71403A patent/YU71403A/sh unknown
- 2002-01-31 ES ES02716247T patent/ES2231681T3/es not_active Expired - Lifetime
- 2002-01-31 MX MXPA03008850A patent/MXPA03008850A/es active IP Right Grant
- 2002-01-31 GE GE5314A patent/GEP20053675B/en unknown
- 2002-01-31 PL PL02365294A patent/PL365294A1/xx not_active Application Discontinuation
- 2002-01-31 EP EP04023150A patent/EP1491541B1/en not_active Expired - Lifetime
- 2002-01-31 DE DE60202452T patent/DE60202452C5/de not_active Expired - Fee Related
- 2002-01-31 HU HU0303644A patent/HUP0303644A3/hu unknown
- 2002-03-21 US US10/104,664 patent/US6579879B2/en not_active Expired - Fee Related
- 2002-03-22 PA PA20028541801A patent/PA8541801A1/es unknown
- 2002-03-27 AR ARP020101134A patent/AR035798A1/es unknown
- 2002-03-27 MY MYPI20021093A patent/MY134304A/en unknown
- 2002-03-27 UY UY27237A patent/UY27237A1/es not_active Application Discontinuation
- 2002-03-27 PE PE2002000246A patent/PE20030007A1/es not_active Application Discontinuation
- 2002-03-28 AP APAP/P/2002/002461A patent/AP2002002461A0/en unknown
- 2002-03-29 TN TNTNSN02037A patent/TNSN02037A1/fr unknown
- 2002-03-29 TW TW091106386A patent/TWI245762B/zh not_active IP Right Cessation
- 2002-03-31 CZ CZ20032563A patent/CZ20032563A3/cs unknown
-
2003
- 2003-02-20 US US10/370,895 patent/US6849629B2/en not_active Expired - Fee Related
- 2003-06-16 IS IS6845A patent/IS2205B/is unknown
- 2003-06-17 ZA ZA200304671A patent/ZA200304671B/en unknown
- 2003-06-25 EC EC2003004671A patent/ECSP034671A/es unknown
- 2003-09-17 MA MA27314A patent/MA27003A1/fr unknown
- 2003-09-17 HR HR20030752A patent/HRP20030752A2/hr not_active Application Discontinuation
- 2003-09-17 BG BG108179A patent/BG108179A/xx unknown
- 2003-09-29 NO NO20034345A patent/NO20034345L/no unknown
-
2004
- 2004-06-24 HK HK04104538A patent/HK1061678A1/xx not_active IP Right Cessation
-
2006
- 2006-01-23 IS IS8250A patent/IS8250A/is unknown
- 2006-01-23 IS IS8251A patent/IS8251A/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1373259E (pt) | Inibidores piridazinona de aldose reductase | |
| CY2015028I2 (el) | Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης | |
| PT1370553E (pt) | Inibidores de rhoquinase | |
| DE60234125D1 (de) | E inhibitoren | |
| ATE397925T1 (de) | Cis-imidazoline als mdm2-hemmer | |
| DE60218138D1 (de) | Rho-kinase inhibitoren | |
| DK3808743T3 (da) | HIV-hæmmende pyrimidin-derivater | |
| NO20041983L (no) | C-5-modifiserte indazolylprrolotriaziner | |
| DK1361880T3 (da) | 6-substituerede pyrido-pyrimidiner | |
| DE60301683D1 (de) | Leseverstärker | |
| NO20042742L (no) | Pyrimidinforbindelser | |
| DE60239456D1 (de) | Amplifizierungsverfahren | |
| DE60201856D1 (de) | Klasse-D Verstärker | |
| NO20013535L (no) | Nöytrofil-funksjons-inhibitorer | |
| DE60222443D1 (de) | Vorverstärkungsschaltung | |
| DE60226690D1 (de) | Rauscharme Vorspannungstechnik | |
| ATA6972001A (de) | Sonnenuhr | |
| SE0100694D0 (sv) | DHFR inhibitors | |
| UA5096S (uk) | Суцільнометалевий піввагон | |
| ITVA20020070A1 (it) | Composizioni farmaceutico-dietetiche comprendenti inibitori della hmg-coa reduttasi e/o polielettroliti. | |
| ATE270267T1 (de) | Scyphostatin-analoga als smase-inhibitoren | |
| ES1050377Y (es) | Grifo monomando mejorado | |
| FI5187U1 (fi) | Kauha | |
| NO20015982A (no) | Mikrofon |